Who are Palbociclib in combination with AI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ibrance, target treatment, Palbociclib, Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant, Trilaciclib, carboplatin, etoposide，or Topotecan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/palbociclib-in-combination-with-ai.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Palbociclib in combination with AI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Palbociclib in combination with AI (palbociclib-in-combination-with-ai) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK inhibitor. Area: Oncology.

marketed CDK inhibitor CDK4/6 Oncology Live · refreshed every 30 min

Target snapshot

Palbociclib in combination with AI (palbociclib-in-combination-with-ai) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Palbociclib in combination with AI TARGET	palbociclib-in-combination-with-ai	Pfizer	marketed	CDK inhibitor	CDK4/6
Ibrance	Palbociclib	Pfizer	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)	2015-01-01
target treatment	target treatment	Institut Bergonié	marketed	CDK4/6 inhibitor	CDK4/6
Palbociclib	palbociclib	Pfizer Inc.	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)
Abemaciclib + Aromatase Inhibitor	Abemaciclib + Aromatase Inhibitor	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + Aromatase inhibitor combination	CDK4/6 + Aromatase
Abemaciclib + Fulvestrant	Abemaciclib + Fulvestrant	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + estrogen receptor antagonist	CDK4/6 and estrogen receptor (ER)
Trilaciclib, carboplatin, etoposide，or Topotecan	Trilaciclib, carboplatin, etoposide，or Topotecan	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	CDK4/6 inhibitor	CDK4/6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK inhibitor class)

Astellas Pharma Europe B.V. · 1 drug in this class
Dyve Biosciences, Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Shirley Vichy Wang · 1 drug in this class
Tego Science, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Palbociclib in combination with AI — Competitive Intelligence Brief. https://druglandscape.com/ci/palbociclib-in-combination-with-ai. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab